

**IN THE UNITED STATES DISTRICT COURT  
DISTRICT OF DELAWARE**

|   |   |                        |
|---|---|------------------------|
| NIPPON SHINYAKU CO., LTD., Plaintiff,   | ) |                        |
|   | ) |                        |
| v.                                      | ) |                        |
|   | ) |                        |
| SAREPTA THERAPEUTICS, INC.,             | ) | C.A. No. 21-1015 (JLH) |
|   | ) |                        |
| Defendant.                              | ) |                        |
|   | ) |                        |
| <hr/>                                   |   |                        |
| SAREPTA THERAPEUTICS, INC.,             | ) |                        |
|   | ) |                        |
| Defendant and Counter-Plaintiff         | ) |                        |
|   | ) |                        |
| v.                                      | ) |                        |
|   | ) |                        |
| NIPPON SHINYAKU CO., LTD. and           | ) |                        |
|   | ) |                        |
| NS PHARMA, INC., Plaintiff and Counter- | ) |                        |
|   | ) |                        |
| Defendants.                             | ) |                        |

**NIPPON SHINYAKU CO., LTD. AND NS PHARMA, INC.’S  
MOTION TO STRIKE CERTAIN SUPPLEMENTAL OPINIONS FROM SAREPTA’S  
ECONOMIC EXPERT JOHN JAROSZ**

Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. hereby move the Court to strike Sarepta Therapeutics, Inc.'s economic expert John Jarosz's supplemental opinions set forth in paragraphs 14-20 of Mr. Jarosz's November 5, 2024 Second Supplemental Expert Report. The reasons for the instant motion are set forth in the accompanying letter brief filed contemporaneously herewith.

Pursuant to Local Rule 7.1.1, the undersigned hereby certifies that counsel for the parties, including lead and Delaware counsel, made a reasonable effort to reach agreement on the subject of the instant motion, including via verbal meet and confer on November 22, 2024, and were unable to reach agreement.

Dated: November 22, 2024

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Amanda S. Williamson (admitted *pro hac vice*)  
Christopher J. Betti (admitted *pro hac vice*)  
Krista V. Venegas (admitted *pro hac vice*)  
Wan-Shon Lo (admitted *pro hac vice*)  
Maria E. Doukas (admitted *pro hac vice*)  
Zachary D. Miller (admitted *pro hac vice*)  
Michael T. Sikora (admitted *pro hac vice*)  
110 N. Wacker Drive, Suite 2800  
Chicago, IL 60601  
Telephone: 312.324.1000  
Fax: 312.324.1001  
amanda.williamson@morganlewis.com  
christopher.betti@morganlewis.com  
krista.venegas@morganlewis.com  
shon.lo@morganlewis.com  
maria.doukas@morganlewis.com  
zachary.miller@morganlewis.com  
michael.sikora@morganlewis.com

Julie S. Goldemberg (admitted *pro hac vice*)  
Alison P. Patitucci (admitted *pro hac vice*)  
2222 Market Street  
Philadelphia, PA 19103  
Telephone: 215.693.5000  
Fax: 215.963.5001  
julie.goldemberg@morganlewis.com  
alison.patitucci@morganlewis.com

David L. Schrader  
300 S Grand Ave 22nd Floor  
Los Angeles, CA 90071  
Telephone: 213.612.2500 | Fax: 213.612.2501  
david.schrader@morganlewis.com

/s/Amy M. Dudash

Amy M. Dudash (DE Bar No. 5741)  
1201 N. Market Street, Suite 2201  
Wilmington, Delaware 19801  
Telephone: 302.574.3000  
Fax: 302.574.3001  
amy.dudash@morganlewis.com

*Attorneys for Nippon Shinyaku Co.,  
Ltd. and NS Pharma, Inc.*